Company Profile

Nature Technology Corporation
Profile last edited on: 2/11/20      CAGE: 3HGF6      UEI: XJ4FJLYHA4Z8

Business Identifier: non-viral vectors (plasmids) and processes for gene therapy and DNA vaccination vector production
Year Founded
1988
First Award
1998
Latest Award
2013
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4701 Innovation Drive
Lincoln, NE 68521
   (402) 472-6530
   natx@natx.com
   www.natx.com
Location: Single
Congr. District: 01
County: Lancaster

Public Profile

Nature Technology Corporation (NTC) is a technology-based biologics development company, providing vector design and construction, process development and manufacturing (OEM) assistance to biotech and bio-pharmaceutical companies. NTC’s mission is to provide essential platform technology and services for the construction, delivery, and expression of new age biologics, including DNA vaccines, gene therapeutics, recombinant proteins. NTC is dedicated to innovating, developing and providing cost-effective, generic solutions for safe, efficient human therapy using viral as well as non-viral systems for gene delivery. This privately held company has acquired exclusive world rights to six issued US Patents (retrotransposon gene delivery platform technology), with additional US and international patents pending. NTC is the leading manufacturer and supplier of highly purified, endotoxin-free DNA molecules and recombinant proteins.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $247,934
Project Title: Miniplasmid Vector Platform For Non-Viral Gene Therapy
2012 2 NIH $1,145,995
Project Title: eukaryotic expression vectors resistant to transgene silencing
2007 1 NIH $207,016
Project Title: Rapid deployment DNA vaccine for pandemic influenza
2007 2 NIH $1,020,183
Project Title: Chimeric enzyme for host nucleic acid autohydrolysis
2005 1 NIH $136,195
Project Title: Antisense inhibitors for enhanced plasmid production

Key People / Management

  Clague Hodgson -- President

  Aaron Carnes -- Director Process Development

  Clague P Hodgson

  Michael Ogden

  Justin Vincent -- Vice President, Business Development and production

  James A Williams -- V.P. Research & Development,

  Mary A Zink